Literature DB >> 32283321

Deep Brain Stimulation Surgery for Essential Tremor in a Patient with Type A Hemophilia.

Ryan Palsma1, Nicholas Gravbrot1, Robert Bina1, Manas Agastya2, Willard S Kasoff3.   

Abstract

BACKGROUND: Hemophilia is generally considered a contraindication to deep brain stimulation (DBS) and other elective intracranial surgery because of the elevated risk of perioperative hemorrhage. Two prior case reports have suggested, however, that DBS may be safe in patients with hemophilia who undergo appropriate factor replacement. Here, we describe a third case of DBS surgery for medically refractory essential tremor (ET) in a patient with hemophilia A. CASE DESCRIPTION: A 68-year-old right-handed man with mild hemophilia A presented for a 10-year history of bilateral (right greater than left), medically refractory ET. The patient was considered an appropriate candidate for DBS by a multidisciplinary movement disorders conference, and hematology consultation was obtained. Baseline preoperative laboratory results showed a quantitative factor VIII (FVIII) level of 38%. Perioperative management consisted of daily intravenous bolus doses of recombinant FVIII from the morning of surgery to postoperative day 10. The patient underwent uncomplicated unilateral DBS placement in the left ventralis intermedius thalamus. Intra- and postoperative imaging showed no hemorrhage. His postoperative course was uncomplicated except for a single self-limited episode of hematuria requiring no intervention.
CONCLUSIONS: DBS placement for ET may be safe in patients with coexisting hemophilia A if appropriate FVIII replacement is given, which may be delivered as bolus infusions rather than continuous infusion.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Deep brain stimulation; Essential tremor; Hemophilia

Year:  2020        PMID: 32283321     DOI: 10.1016/j.wneu.2020.03.174

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  1 in total

1.  Case report: successful perioperative management of patients with haemophilia A using an extended half-life factor VIII (Efmoroctocog alfa) during neurosurgical procedures.

Authors:  Florian Kocher; Andreas Seeber; Johannes Kerschbaumer; Stefan Schmidt; Dominik Wolf; Clemens Feistritzer
Journal:  Ther Adv Hematol       Date:  2021-03-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.